Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

ABSTRACT:

Background

In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these early efficacy metrics are still predictive of long-term clinical benefit such as overall survival. The goal of this paper is to identify appropriate early efficacy metrics predictive of overall survival for immunotherapy trials.

Methods

Based on several checkpoint blockade based immunotherapy studies in metastatic melanoma, we evaluated the predictive value of early tumor size changes and RECIST-based efficacy metrics at various time points on overall survival. The cut-off values for tumor size changes to predict survival were exp

SUBMITTER: Wang M 

PROVIDER: S-EPMC6368769 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature